NCPA Media: Health Care
Sep 20, 2016
Dallas, TX (9/20/2016) – Drug therapy represents the greatest value in the U.S. health care system – but, if policymakers limit cost-sharing, many drug prices will skyrocket, warns a new study by National Center for Policy Analysis Senior Fellow Devon Herrick.
Aug 29, 2016
ONE News Now: Senior Fellow Devon Herrick walks us through what health care shoppers need to consider as open enrollment approaches in an article at One News Now.
Aug 25, 2016
Oncology Times: For consumers, MACRA's increased federal control over the practice of medicine could translate into “higher costs and more difficulties getting access to timely and quality care,” warned Senior Fellow John Graham in an article at the Oncology Times.
Aug 25, 2016
CNN: Senior Fellow Devon Herrick’s research on generic drugs is cited in an article at CNN laying out six ways to pay less for your prescription drugs.
Jul 20, 2016
Initial Assessments Reveal Increased Regulation, Costs: NCPA
Dallas, TX (7/20/2016) – The “doc fix” contained in the Medicare Access and CHIP Reauthorization Act (MACRA) is fiscally irresponsible, and will only increase federal control over how doctors practice medicine, warns a new report by National Center for Policy Analysis Senior Fellow John R. Graham.
Jul 08, 2016
E-prescribing is Key to Reducing Fraud & Abuse
Dallas, TX (7/8/2016) – Today’s vote on a House bill to reduce opioid abuse did not include a key solution to the growing opioid pan reliever epidemic: mandatory electronic prescribing. E-prescribing would make a significant dent in the rate of fraud, resale and abuse of opioids, according to a new study by National Center for Policy Analysis Senior Fellow Devon Herrick.
Jun 21, 2016
Overregulating Drug Plans Could Raise Costs to Consumers: NCPA
Would requiring disclosure of wholesale prices lower prescription drug costs? Experts say no, according to a new report by National Center for Policy Analysis Senior Fellow Devon Herrick.
In a misguided attempt to combat the high prices of some new and specialty drugs, a few politicians and trade lobbyists for pharmacies and drug makers have begun to blame high drug prices on the administrators of employee drug plans – suggesting drug plans are not passing on their discounts to consumers and employers.
This “bogus argument” posits that drug prices would be lower if drug plans were required to disclose the wholesale prices – a requirement that would be detrimental to any wholesale industry.
Regardless of the industry, wholesale prices are often negotiated among private parties and are generally considered proprietary. “If competing hardware stores knew the exact wholesale prices Home Depot negotiated with suppliers, all competing stores would bargain aggressively for the same price. Over time, the likely result is that manufacturers would ultimately set one uniform wholesale price higher than the price volume purchasers would otherwise obtain,” says Herrick.
The end result? Highly competitive firms would no longer be able to leverage buying power and pass on discounted prices to consumers.
“Drugs are affordable for most consumers because of competition among Pharmacy Benefit Managers (PBMs),” adds Herrick. “Taking away PBMs’ ability to compete by regulating price transparency would harm consumers in the long run."
A Bogus Solution for High Drug Costs: http://www.ncpa.org/pub/a-bogus-solution-for-high-drug-costs
Jun 02, 2016
NCPA research recently released in the report “How to Pay for Medicare” was cited in this article from McKnight’s.